Salute e Benessere
Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT® in brain cancer patients
Today's news means Curasight is now in clinical development with both its diagnostic (uTRACE) and therapeutic (uTREAT) platforms.
CEO Ulrich Krasilnikoff and continues,
The trial aims to investigate Curasight's uTREAT as a new type of targeted radiopharmaceutical therapy in glioblastoma patients. Participants in the trial are patients with newly diagnosed verified or suspected GBM. The trial design is informed from research and earlier studies with uTRACE® as well as protocol discussions with Key Opinion Leaders.
Curasight's uPAR theranostic platform combines two key technologies - uTRACE and uTREAT both targeting the uPAR receptor. uTRACE is designed to deliver sensitive imaging for diagnosis, while uTREAT offers a targeted radiopharmaceutical solution. Together, they form an integrated approach to improving the diagnosis and treatment of cancers that express uPAR. Curasight's ambition is to develop both uTRACE and uTREAT to improve diagnosis and treatment of uPAR-expressing cancers.
Treatment of glioblastoma and other high-grade gliomas (WHO grades 3 or 4) presents a significant unmet medical need, necessitating innovative and effective treatments. A total of approx. 65,000 patients are diagnosed with primary brain tumors and more than 30,000 patients are diagnosed annually with the most aggressive form, glioblastoma, in the US and EU. Approximately 10 % of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50% of the patients die within 14 months and after five years from diagnosis only 5% are still alive. External beam radiation is a cornerstone in the therapy of brain cancers. uTREAT could potentially replace or reduce the use of external beam radiation and thereby lower side effects to the healthy brain due to more specific tumor tissue targeting.
Ulrich Krasilnikoff , CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/curasight/r/curasight-announces-acceptance-of-clinical-trial-application--cta--for-phase-1-trial-with-utreat--in,c4222865
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/curasight-announces-acceptance-of-clinical-trial-application-cta-for-phase-1-trial-with-utreat-in-brain-cancer-patients-302538481.html